Competitive DRUGS Act of 2019

Summary

Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 or the Competitive DRUGS Act of 2019 This bill authorizes the Federal Trade Commission to initiate a proceeding against parties to an agreement resolving or settling a patent infringement claim in connection with the sale of a drug. Such an agreement is generally presumed to be an unfair method of competition and is a violation of this bill if the filer of the generic drug application receives something of value and agrees to limit or forgo research, development, manufacturing, marketing, or sales of the generic drug. However, an agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market the generic drug prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on a claim that the generic drug infringes a patent. An agreement if also exempt if the agreement's pro-competitive benefits outweigh its anticompetitive effects. The bill establishes penalties for violations of the bill.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 25 February 2019

   Introduced

   Referred to the Committee on Ways and Means, and in addition to the Committees on Energy and Commerce, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 25 February 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

3. 25 February 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 25 February 2019

   Introduced

   Introduced in House

   Source: IntroReferral

5. 26 February 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

6. 25 March 2019

   Referred

   Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 25 February 2019 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 25 February 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 25 February 2019

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 25 February 2019

  Open at official source

Sponsors

• Rep. Doggett, Lloyd [D-TX-37] · D · Sponsor
• Earl Blumenauer · D · Sponsor
• Matt Cartwright · D · Sponsor
• Rep. Chu, Judy [D-CA-28] · D · Sponsor
• ELIJAH CUMMINGS · D · Sponsor
• Rosa DeLauro · D · Sponsor
• Rep. DeSaulnier, Mark [D-CA-10] · D · Sponsor
• Raúl Grijalva · D · Sponsor
• Katie Hill · D · Sponsor
• Rep. Kaptur, Marcy [D-OH-9] · D · Sponsor
• Rep. Khanna, Ro [D-CA-17] · D · Sponsor
• Rep. Moore, Gwen [D-WI-4] · D · Sponsor
• Grace Napolitano · D · Sponsor
• Alexandria Ocasio-Cortez · D · Sponsor
• Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Sponsor
• Rep. Pingree, Chellie [D-ME-1] · D · Sponsor
• Rep. Pocan, Mark [D-WI-2] · D · Sponsor
• Maxine Waters · D · Sponsor
• Sen. Welch, Peter [D-VT] · D · Sponsor
• JAMES LANGEVIN · D · Sponsor
• Rep. Garamendi, John [D-CA-8] · D · Cosponsor
• Katie Porter · D · Cosponsor
• · hsju00 · Standing
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to → Preserve Access to Affordable Generics and Biosimilars Act
• related to ← Preserve Access to Affordable Generics and Biosimilars Act
• related to ← Competitive DRUGS Act of 2017